Annual revenue rose from 909 eok won in 2023 (1 eok = 100 million won) to 1,051 eok won in 2024 (up 15.7% year on year) and 1,135 eok won in 2025 (up 8.0% year on year), increasing for two consecutive years from 2024 to 2025. Among 2023–2025, the largest year was 2025 and the smallest was 2023.
Operating profit fell from 165 eok won in 2023 to 150 eok won in 2024 (down 8.7% year on year), then recovered to 170 eok won in 2025 (up 13.0% year on year).
Regarding the 2024 decline, Edaily analyzed that results for core products such as fillers, lifting threads, and Korean medicine acupuncture needles improved, but results for other Korean medicine supplies decreased. The operating margin was 18.1% in 2023, 14.3% in 2024, and 15.0% in 2025.
Net profit attributable to controlling shareholders fluctuated widely: 97.7 eok won in 2023, 29.1 eok won in 2024 (down 70.2% year on year), and 117 eok won in 2025 (up 301.6% year on year).
Over the same period, net profit including non-controlling interests was 97.3 eok won, 31.3 eok won, and 114 eok won, which differs from net profit attributable to controlling shareholders.
In 2024, the decline in net profit attributable to controlling shareholders (70.2%) was far larger than the decline in operating profit (8.7%), so items below operating profit must be examined together to interpret the result.
Operating cash flow was 62.8 eok won in 2023, 185 eok won in 2024, and 120 eok won in 2025, decreasing in 2025. Looking at the quarterly trend, operating profit rose from 40.6 eok won on revenue of 300 eok won in Q3 2025 to 55.3 eok won on revenue of 298 eok won in Q4 2025.
In Q1 2026, revenue was 314 eok won, operating profit was 60.5 eok won, and net profit attributable to controlling shareholders was 54 eok won, which was the peak for that measure.
Revenue in Q2 2026 was 339 eok won, the largest of the last five quarters, but net profit attributable to controlling shareholders fell to 41.4 eok won. Revenue in Q3 2026 was 293 eok won (down 13.8% from the previous quarter), and operating profit was 54.3 eok won (up 33.7% from the same quarter a year earlier).
Net profit attributable to controlling shareholders in the same quarter was 24 eok won (down 19.1% from the same quarter a year earlier). The sum of net profit attributable to controlling shareholders for the last four quarters (Q4 2025 to Q3 2026) is 156 eok won.